Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis

Written by Daisy Ng-Mak, Vanita Tongbram, Kerigo Ndirangu, Krithika Rajagopalan & Antony Loebel

Currently, there are no head-to-head trials comparing the efficacy and metabolic parameters of lurasidone and brexpiprazole for patients with acute schizophrenia. Daisy Ng-Mak and colleagues conducted a network meta-analysis to address this important question. Read the abstract below to find out more on this study, or read the full-text article in Journal of Comparative Effectiveness Research here. Aim: To assess the relative efficacy and metabolic effects of lurasidone and brexpiprazole in the acute treatment of schizophrenia. Methods: Five lurasidone and three brexpiprazole trials were identified. In the absence of head-to-head trials, a Bayesian network meta-analysis comparing lurasidone and brexpiprazole was...

To view this content, please register now for access

It's completely free